Evolus, Inc. (NASDAQ:EOLS) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for standing by. Welcome to Evolus Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Evolus Inc. (EOLS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 5,356,622 | $86,777,276 | -7% | 1.83% |
| 2. | Tang Capital Management Kevin C. Tang | 4,847,399 | $78,527,864 | 5.6% | |
| 3. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,824,849 | $45,762,554 | -3% | 2.31% |
| 4. | Stonepine Capital Timothy P. Lynch | 1,369,821 | $22,191,100 | -18% | 14.02% |
| 5. | Great Point Partners Jeffrey Jay And David Kroin | 1,170,000 | $18,954,000 | -53% | 5.57% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.41 | 174,967 | Director | 275,550 | 2023-08-15 | Filing | |
| $11.11 | 14,043 | Large Shareholder | 7,296,543 | 2021-08-13 | Filing | |
| $10.99 | 23,000 | Large Shareholder | 7,282,500 | 2021-08-12 | Filing | |
| $10.78 | 1,091 | Director | 10,000 | 2022-09-12 | Filing | |
| $10.35 | 8,909 | Director | 8,909 | 2022-09-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.98 | 3,276 | Officer | 148,502 | 2024-09-06 | Filing | |
| $15.85 | 5,631 | Officer | 82,375 | 2024-08-30 | Filing | |
| $12.59 | 175,940 | Officer, Director | 533,349 | 2024-06-06 | Filing | |
| $12.92 | 155,278 | Officer, Director | 533,349 | 2024-06-05 | Filing | |
| $12.73 | 140,214 | Officer, Director | 533,349 | 2024-06-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,339,377 | $35,163,640 | 0% | |
| 2. | 2,943,512 | $30,995,181 | 0% | |
| 3. | 2,582,711 | $27,195,949 | 0% | |
| 4. | 1,414,526 | $14,894,959 | 0% | |
| 5. | 1,317,856 | $13,877,024 | 4.67% |
News See All
Top 10 Holdings of Caligan Partners
Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds.
Evolus, Inc. (NASDAQ:EOLS) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, everyone and thank you for standing by. Welcome to Evolus' Second Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded and webcast live.
Evolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call Transcript
Evolus, Inc. misses on earnings expectations. Reported EPS is $-0.22295 EPS, expectations were $-0.07.
11 Best Low Price Pharma Stocks To Invest In
In this piece, we will take a look at the 13 best low price pharma stocks to invest in.
10 Stocks George Soros and Insiders Are Crazy About
In this article, we will take a detailed look at the 10 Stocks George Soros and Insiders Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks George Soros and Insiders Are...
Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for standing by. Welcome to Evolus' Fourth Quarter and Full Year 2023 Earnings Conference Call.
11 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the 11 best small cap pharma stocks to invest in.
5 Most Promising Long-Term Stocks According to Analysts
In this piece, we will take a look at the five most promising long-term stocks according to analysts.
Evolus, Inc. (NASDAQ:EOLS) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Evolus Third Quarter 2023 Earnings Conference Call. [Operator Instructions]. I would now like to turn the conference over to your host, Mr.